TAFASITAMAB

Brand name:

• Minjuvi®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Submission sponsor:

SPECIALISED THERAPEUTICS ALIM PTY LTD

Condition/indication:
(therapeutic use)

• Relapsed and/or refractory follicular lymphoma (FL)

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC Submission type:

New PBS listing (Matters arising/Matters outstanding)

Comment:

--

Other PBAC consideration:

• TAFASITAMAB

Submission received for:

March 2026 PBAC meeting

Opportunity for consumer comment:

Open 30/07/2025 and close 24/09/2025 (see PBS Website)

PBAC meeting:

Held on 11/03/2026

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

07/04/2026

Lodgement of required documentation:

15/04/2026

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 12/05/2026

Status:

Finalised

7Government processes:

Commenced on 22/05/2026

8Medicine listed on the PBS:

Has not yet occurred